Acute Coronary Syndromes

The Dynamics of Contemporary Oral Antiplatelet Therapy for Acute Coronary Syndromes and Secondary Prevention

Print This Post Print This Post

CME Information

Program Overview

In this symposium, expert faculty members will address the following needs of primary care clinicians: awareness of fundamental pharmacologic profiles (pharmacokinetics, pharmacodynamics, and pharmacogenetics) of clopidogrel, prasugrel, and ticagrelor and the basic concept of clopidogrel resistance; explanation of clinical efficacy and safety data from outcomes trials with oral antiplatelet drugs in ACS patients; identification of appropriate duration of dual antiplatelet therapy (DAPT), based on guideline recommendations, to prevent recurrent ischemic events as well as circumstances where bleeding risks on DAPT may outweigh the need for continuation of dual therapy; and elaboration of best practices in long-term secondary prevention—utilizing guideline-recommended therapies and achieving cardiometabolic goals—to reduce patient risk. Recommendations from new guidelines (for example, from the ACC/AHA Cholesterol guidelines released at the 2013 AHA Scientific Sessions in Dallas, TX) will be incorporated into the educational content to provide attendees with up-to-date information and state-of-the-art management strategies.


Learning Objectives

After completing this activity, the participant should be better able to:

  1. Summarize fundamental similarities and differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics of oral antiplatelet drugs
  2. Explain efficacy and safety data with oral antiplatelet therapies from ACS outcomes trials
  3. Recognize guideline-based therapies to reduce risk and goals to achieve in the management of patients who have experienced an acute coronary syndrome

This activity has expired and is no longer available for CME; however, we hope you still enjoy the education.

If you are using a mobile device, this activity may not view properly.

Published September 2, 2014